References
- Pruthi J, Medkiff KA, Esrason KT et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl.7, 811–815 (2001).
- Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med.349, 931–940 (2003).
- Neuberger J, Portmann B, Macdougall BR et al. Recurrence of primary biliary cirrhosis after liver transplantation. N. Engl. J. Med.306, 1–4 (1982).
- Gautam M, Cheruvattath R, Balan V. Recurrent disease after liver transplantation. Liver Transpl.12, 1813–1824 (2006).
- Gores GJ, Moore SB, Fisher LD et al. Primary biliary cirrhosis: associations with Class II major histocompatibility complex antigens. Hepatology7, 889–892 (1987).
- Klein R, Huizenga JR, Gips CH et al. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J. Hepatol.20, 181–189 (1994).
- Hubscher S, Elias E, Buckels J et al. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J. Hepatol.18, 173–184 (1993).
- Neuberger JM. Recurrent primary biliary cirrhosis. Liver Transpl.9, 539–546 (2003).
- Garcia R, Garcia C, McMaster P et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology33, 22–27 (2001).
- Wong PYN, Portmann B, O’Grady JG et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. J. Hepatol.17, 284–287 (1993).
- Dmitrewski J, Hubscher SG, Mayer AD et al. Recurrent PBC, PSC, and autoimmune hepatitis in the liver allograft: the effect of immunosuppression. J. Hepatol.24, 253–257 (1996).
- Neuberger J, Gunson B, Hubscher S et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl.10, 488–491 (2004).
- Minder D, Boni J, Schupbach J et al. Immunophilins and HIV-1 infection. Arch. Virol.147, 1531–1542 (2002).
- Fauvel H, Marchetti P, Obert G et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. Am. J. Crit. Care Med.165, 449–455 (2002).
- Sutton I, Neuberger J. Primary biliary cirrhosis: seeking the silent partner of autoimmunity. Gut50, 743–746 (2002).
- Wiesner RH, Ludig J, Lindor KD et al. Controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N. Engl. J. Med.322, 1419–1424 (1990).
- Lombard M, Portmann B, Neuberger J et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology104, 519–526 (1993).
- Mazariegos GV, Reyes J, Marino IR et al. Weaning of immunosuppression in liver transplant recipients. Transplantation63, 243–249 (1997).
- Yoshida EM, Singh RA, Vartanian RK et al. Late recurrent post-transplant primary biliary cirrhosis in British Columbia. Can. J. Gastroenterol.11, 229–233 (1997).
- Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology106, 1284–1290 (1994).
- Angulo P, Batts KP, Therneau TM et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology29, 644–647 (1999).
- Corpechot C, Carrat F, Bahr A et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology128, 297–303 (2005).
- Guy JE, Qian P, Lowell JA et al. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl.11, 1252–1257 (2005).
- Charatcharoenwitthaya P, Pimentel S, Talwalkar J et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transplant.13, 1236–1245 (2007).
- Sheng R, Campbell WL, Zajko AB et al. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. Am. J. Roentgenol.166, 1109–1113 (1996).
- Harrison RF, Davies MH, Neuberger JM et al. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology20, 356–361 (1994).
- Graziadei IW, Wiesner RH, Batts KP et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology29, 1050–1056 (1999).
- Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl.8, 575–581 (2002).
- Jeyarajah DR, Netto GJ, Lee SP et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation. Transplantation66, 1300–1306 (1998).
- Brandsaeter B, Schrumpf E, Bentdal O et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl.11, 1361–1369 (2005).
- Vera A, Moledina S, Gunson B et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet360, 1943–1944 (2002).
- Cholongitas E, Shusang V, Papatheodoridis GV et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl.14, 138–143 (2008).
- Khettry U, Keaveny A, Goldar-Najafi A et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum. Pathol.34, 1127–1136 (2003).
- Kugelmas M, Spiegelman P, Osgood MJ et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl.9, 727–732 (2003).
- Alexander J, Lord JD, Yeh MM et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl.14, 245–251 (2008).
- Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Liver Transpl.7, S99–S108 (2001).
- Rowe IA, Webb K, Gunson BK et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl. Int.21, 459–465 (2008).
- Mitchell SA, Bansi DS, Hunt N et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology121, 900–907 (2001).
- Okolicsanyi L, Groppo M, Floreani A et al. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig. Liver Dis.35, 325–331 (2003).
- Pardi DS, Loftus EV Jr, Kremers WK et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology124, 889–893 (2003).
- Loftus EV Jr, Aguilar HI, Sandborn WJ et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology27, 685–690 (1998).
- Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig. Dis. Sci.40, 435–456 (1995).
- Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet1, 735–737 (1973).
- Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl.12, 1813–1824 (2006).
- Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol.31, 929–938 (1993).
- Hennes EM, Zeniya M, Czaja AJ et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology48, 169–176 (2008).
- Ahmed M, Mutimer D, Hathaway M et al. Liver transplantation for autoimmune hepatitis; a 12-year experience. Transplant. Proc.29, 496 (1997).
- Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology120, 239–249 (2001).
- Götz G, Neuhaus R, Bechstein WO et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant. Proc.31, 430–431 (1999).
- Ratziu V, Samuel D, Sebagh M et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease . J. Hepatol.30, 131–141 (1999).
- Reich DJ, Fiel I, Guarrera JV et al. Liver transplantation for autoimmune hepatitis. Hepatology32, 693–700 (2000).
- González-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl.7, 302–310 (2001).
- Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl.7, 285–291 (2001).
- Milkiewicz P, Hubscher SG, Skiba G et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation68, 253 (1999).
- Balan V, Ruppert K, Demetris AJ et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology48, 878–888 (2008).
- Neuberger J, Portmann B, Calne R et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation37, 363–365 (1984).
- Prados E, Cuervas-Mons V, de la Mata M et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation66, 1645–1650 (1998).
- Wright HL, Bou-Abboud CF, Hassanein T et al. Disease recurrence and rejection following transplantation for autoimmune chronic active liver disease. Transplantation53, 136–139 (1992).
- Ayata G, Gordon FD, Lewis WD et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology32, 185–192 (2000).
- Neuberger J, Portmann B, Calne R et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation37, 363–365 (1984).
- Rumbo C, Morotti RA, Gondolesi G et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J. Transplant.5, 1085–1089 (2005).
- Hurtova M, Duclos-Vallée JC, Johanet C et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl.7, 556–558 (2001).
- Adams LA, Sanderson S, Lindor KD et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol.42, 132–138 (2005).
- Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease; American Gastroenterological Association. Gastroenterology123, 1705–1725 (2002).
- Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology49, 306–317 (2009).
- Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann. Intern. Med.111, 473–478 (1989).
- Heurtier A, Gombert S, Giral P et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology128, 1898–1906 (2005).
- Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology46, 582–589 (2007).
- Huwart L, Sempoux C, Vicaut E et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology135, 32–40 (2008).
- Burke GW 3rd, Cirocco R, Hensley G et al. Liver transplantation for cirrhosis following jejunoileal bypass-regional cytokine differences associated with pathological changes in the transplant liver. Transplantation54, 374–377 (1992).
- Kim WR, Poterucha JJ, Porayko MK, Dickson RE, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation62, 1802–1805 (1996).
- Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl. Surg.3, 174–176 (1997).
- Molloy RM, Komorowski R, Varma RR. Recurrent non-alcoholic steatothepatitis and cirrhosis after liver transplantation. Liver Transpl. Surg.3, 117–178 (1997).
- Contos MJ, Cales W, Sterling RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl.7, 363–373 (2001).
- Charlton M, Kasparova P, Weston S et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl.7, 608–614 (2001).
- Sutedja DS, Gow PJ, Hubscher SG, Elias E. Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy. Transpl. Proc.36, 2334–2337 (2004).
- Cauble MS, Gilroy R, Sorrell MF et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation71, 892–895 (2001).
- Ong J, Younossi ZM, Reddy V et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl.7, 797–801 (2001).
- Benten D, Staufer K, Sterneck M. Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat. Clin. Pract. Gastroenterol. Hepatol.6, 23–36 (2009).
- Okita M, Hayashi M, Sasagawa T et al. Effect of moderately energy-restricted diet on obese patients with fatty liver. Nutrition17, 542–547 (2001).
- Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology99, 1408–1413 (1990).
- Suzuki A, Lindor K, St Saver Jet al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J. Hepatol.43, 1060–1066 (2005).
- Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol.27, 103–107 (2007).
- de Almeida SR, Rocha PR, Sanches MD et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes. Surg.16, 270–278 (2006).
- Barker KB, Palekar NA, Bowers SP et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am. J. Gastroenterol.101, 368–373 (2006).
- Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology46, 122–129 (2007).
- Harrison SA, Fincke C, Helinski D et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment. Pharmacol. Ther.20, 623–628 (2004).
- Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut56, 443–444 (2007).
- Tushuizen ME, Bunck MC, Pouwels PJ et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int.26, 1015–1017 (2006).
- Aithal GP, Thomas JA, Kaye PV et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology135, 1176–1184 (2008).
- Sanyal AJ, Mofrad PS, Contos MJ et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis. Clin. Gastroenterol. Hepatol.2, 1107–1115 (2004).
- Belfort R, Harrison SA, Brown K et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355, 15–25 (2006).
- Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone for nonalcoholic steatohepatitis. Hepatology39, 188–196 (2004).
- Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J.Gastroenterol.100, 1082–1090 (2005).
- Nair S, Diehl AM, Wiseman M et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther.20, 23–28 (2004).
- Yokohama S, Tokusashi Y, Nakamura K et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate activation in non-alcoholic steatohepatitis. World J. Gastroenterol.12, 322–326 (2006).
- Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA et al. A pilot study of atorvastatin treatment in dyslipidemidic, non-alcoholic fatty liver patients. Aliment. Pharmacol. Ther.23, 1643–1647 (2006).
- Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with non-alcoholic steatohepatitis. Hepatology40, 1222–1225 (2004).
- Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with non-alcoholic steatohepatitis. J. Hepatol.31, 384 (1999).
- Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation15, 1141–1150 (2007).
- Neuberger J, Adams D, MacMaster P, Maidment A, Speed M. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ18, 172–175 (1998).
- Lucey MR, Merion RM, Henley KS et al. Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology102, 1736–1741 (1992).
- Bird GL, O’Grady JG, Harvey FA et al. Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. BMJ301, 15–17 (1990).
- DiMartini AF, Jain A, Irish W et al. Liver transplantation in alcoholic and non-alcoholic cirrhosis: survival according to UNOS status, medical variables, and sobriety. Transplantation66, 298–302 (1998).
- Fábrega E, Crespo J, Casafont F et al. Alcoholic recidivism after liver transplantation for alcoholic cirrhosis. J. Clin. Gastroenterol.26, 204–206 (1998).
- Pageaux GP, Michel J, Coste V et al. Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism. Gut45, 421–426 (1999).
- Pageaux GP, Bismuth M, Perney P et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J. Hepatol.38, 629–634 (2003)
- Cuadrado A, Fabrega E, Casafont F et al. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl.11, 420 426 (2005).
- Conjeevaram HS, Hart J, Lissoos TW et al. Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. Transplantation67, 1562–1568 (1999).
- Pfitzmann R, Schwenzer J, Rayes N et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl.13, 197–205 (2007).
- Tang H, Boulton R, Gunson B et al. Patterns of alcohol consumption after liver transplantation. Gut43, 140–145 (1998).
- Foster PF, Fabrega F, Karademir S et al. Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology25, 1469–1477 (1997).
- Zibari GB, Edwin D, Wall L et al. Liver transplantation for alcoholic liver disease. Clin. Transplant.10, 676–679 (1996).
- Jauhar S, Talwalkar JA, Schneekloth T et al. Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl.10, 408–411 (2004).
- Gish RG, Lee A, Brooks L et al. Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. Liver Transpl.7, 581–587 (2001).
- Hillebrand DJ, Voigt M, La Breque DR. Liver transplantation in alcoholic patients: importance of pre-transplantation variables in predicting recidivism among various liver disease subgroups. Hepatology26, A523 (1997).
- Tripp LE, Clemons JR, Goldstein RR et al. Drinking patterns in liver transplant recipients. Psychosomatics37, 249–253 (1996).
- Coffman KL, Hoffman A, Sher L et al. Treatment of the postoperative alcoholic liver transplant recipient with other addictions. Liver Transpl. Surg.3, 322–327 (1997).
- Perney P, Bismuth M, Sigaud H et al. Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease? Transpl. Int.18, 1292–1297 (2005).
- De Gottardi A, Spahr L, Gelez P et al.A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch. Intern. Med.167, 1183–1188 (2007).
- Lim JK, Keeffe EB. Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. Liver Transpl.10, S31–S38 (2004).
- Raakow R, Langrehr R, Lohmann M et al. Is orthotopic liver transplantation for end-stage alcoholic cirrhosis justified? Transplant. Proc.27, 1241–1242 (1995).
- Bravata DM, Olkin I, Barnato AE et al. Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: a systematic review. Liver Transpl.7, 191–203 (2007).
- Miguet M, Monnet E, Vanlemmens C et al. Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. Gastroenterol. Clin. Biol.28, 845–851 (2004).
- Niemelä O. Biomarkers in alcoholism. Clin. Chim. Acta377, 39–49 (2007).
- DiMartini A, Day N, Dew MA et al. Alcohol use following liver transplantation: a comparison of follow-up methods. Psychosomatics42, 55–62 (2001).
- Schmitt VM, Stieber P, Jungst D et al. Carbohydrate-deficient transferrin is not a useful marker for the detection of chronic alcohol abuse. Eur. J. Clin. Invest.28, 615–621 (1998).
- Heinemann A, Sterneck M, Kuhlencordt R et al. Carbohydrate-deficient transferrin: diagnostic efficiency among patients with end-stage liver disease before and after liver transplantation. Alcohol Clin. Exp. Res.22, 1806–1812 (1998).
- Berlakovich GA, Windhager T, Freundorfer E et al. Carbohydrate-deficient transferrin for detection of alcohol relapse after orthotopic liver transplantation for alcoholic cirrhosis. Transplantation67, 1231–1235 (1999).
- Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs.18, 485–504 (2004).
- Georgiou G, Webb K, Griggs K et al. First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation. Liver Transpl.9, 772–775 (2003).
- Björnsson E, Olsson J, Rydell A et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand. J. Gastroenterol.40, 206–216 (2005).
- Weinrieb RM, Van Horn DH, McLellan AT et al. Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. Psychosomatics42, 110–116 (2001).
- Garcia-Pagán JC, Heydtmann M, Raffa S et al. TIPS for Budd–Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology135, 808–815 (2008).
- Putnam CW, Porter KA, Weil R 3rd et al. Liver transplantation for Budd–Chiari syndrome. JAMA236, 1142–1143 (1976).
- Cruz E, Ascher NL, Roberts JP et al. High incidence of recurrence and hematologic events following liver transplantation for Budd–Chiari syndrome. Clin. Transplant.19, 501–506 (2005).
- Mentha G, Giostra E, Majno PE et al. Liver transplantation for Bu–Chiari syndrome: a European study on 248 patients from 51 centres. Hepatology44, 520–528 (2006)
- Tan HP, Markowitz JS, Maley WR et al. Successful liver transplantation in a patient with Budd–Chiari syndrome caused by homozygous factor V Leiden. Liver Transpl.6, 654–656 (2000).
- Casella JF, Lewis JH, Bontempo FA et al. Successful treatment of homozygous protein C deficiency by hepatic transplantation. Lancet27, 435–438 (1988).
- Melear JM, Goldstein RM, Levy MF et al. Hematologic aspects of liver transplantation for Budd–Chiari syndrome with special reference to myeloproliferative disorders. Transplantation27, 1090–1095 (2002).
- Jamieson NV, Williams R, Calne RY. Liver transplantation for Budd–Chiari syndrome, 1976–1990. Ann. Chir.45, 362 (1991).
- Halff G, Todo S, Tzakis AG et al. Liver transplantation for the Budd–Chiari syndrome. Ann. Surg.211, 43 (1990).
- Srinivasan P, Rela M, Prachalias A et al. Liver transplantation for Budd–Chiari syndrome. Transplantation73, 973 (2002).